|
Private Sector | Not Classified - india | PID: 147567
|
|
Cipla, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, has signed an agreement with Serum Institute of India (SII) - a global leader in the production of vaccines - to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SII will develop and manufacture the vaccine, and Cipla will exclusively market it in India. The vaccine will be manufactured in Serum’s world class production facilities approved by the WHO
| Updated on: 28 - May - 2015
|
|
|
|
|
|
|